OBJECTIVE： To observe the improvement effects of angiotensin converting enzyme inhibitor （ACEI） fosinopril， perindopril and benazepril on ventricular remodeling in patients with acute myocardial infarction （AMI）， and to evaluate its safety. METHODS： A total of 96 AMI patients selected from our hospital during Jan. 2014-Oct. 2016 were divided into group A， B， C according to random number table， with 32 cases in each group. All patients received symptomatic treatment， underwent percutaneous coronary intervention， and then given ACEI after blood vessels recanalization and keeping blood pressure stable. Group A was given Fosinopril sodium tablets 10 mg， qd； group B was given Perindopril tert-butylamine tablets 4 mg， qd； group C was given Benazepril hydrochloride tablets 10 mg， qd. All groups were treated for consecutive 6 months. Cardiac structure and function indexes （LVESD， LVEDD， IVSD， LVPWD， LVEF， CO）， hemodynamic indexes （SBP， DBP， HR） and related lab indexes （FPG， TG， TC， HDL-C， LDL-C， AST， ALT， Scr， BUN） of 3 groups were observed before and after treatment. The occurrence of ADR was recorded. RESULTS： Before treatment， there was no statistical significance in cardiac structure and function indexes， hemodynamic indexes or related lab indexes among 3 groups （P＞0.05）. After treatment， the levels of LVESD， LVEDD， LVPWD， CO， HR， FPG， TG， TC and LDL-C in 3 groups were decreased significantly， while the levels of LVEF and SBP were increased significantly， with statistical significance （P＜0.05）. There was no statistical significance in above indexes among 3 groups after treatment （P＞0.05）. After treatment， the level of Scr in group B was significantly increased and higher than group A and C， with statistical significance （P＜0.05）. There was no statistical significance in the levels of IVSD， DBP， HDL-C， AST， ALT or BUN among 3 groups before and after treatment as well as the level of Scr between group A and C （P＞0.05）. There was no statistical significance in the incidence of ADR among 3 groups（P＞0.05）. CONCLUSIONS： Fosinopril， perindopril and benazepril can significantly improve ventricular remodeling in AMI patients， narrowing the heart cavity， increasing systolic pressure， lowering heart rate， reducing the oxygen consumption of the ventricle， with similar effects. Perindopril may increase the level of Scr， so fosinopril and benazepril are safe and suitable for AMI patients with renal function disorder.